Abstracts of the 2007th Maruyama Memorial Lectures of the 76th Annual Meeting of the Medical Association of Nippon Medical School

Date: September 6, 2008 Place: Nippon Medical School

Abstracts of the 2007th Maruyama Memorial Research Fund Prize Memorial Lecture (1)

Study of MicroRNA Expression Profiles of Esophageal Cancer

Takuya Mishima¹, Ichiro Akagi², Masao Miyashita², Osamu Ishibashi¹, Yoshiaki Mizuguchi¹², Takashi Tajiri² and Toshihiro Takizawa¹

¹Molecular Anatomy and Medicine, Graduate School of Medicine, Nippon Medical School ²Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School

MicroRNAs (miRNAs), which are "tiny" RNA molecules (approximately 22 nucleotides in length), were long thought to be "junk" RNA because they were transcribed from genomic DNA that does not encode information for making proteins. Now, miRNAs are believed to be important posttranscriptional molecules that can regulate the expression of complementary messenger RNA targets¹²; miRNAs have been associated with a variety of physiological and pathological events³⁻⁵. We are now studying miRNA expression profiles of esophageal cancer. According to the cancer statistics of the Foundation for Promotion of Cancer Research (http://www.fpcr.or.jp/ publication/pdf/statistics2008.pdf), the esophageal cancer death rate in Japan is 4.8% (15.4 deaths/100,000 persons) among males and 1.3% (4.17 deaths/100,000 persons) among females. Thus, approximately 10,000 persons die of esophageal cancer each year in Japan. Although comprehensive treatment, including surgery, chemotherapy, and radiotherapy, contributes to the yearly improvements in the survival rate of patients with esophageal cancer, esophageal cancer remains a cancer with an extremely poor prognosis. In Japan, more than 90% of esophageal cancers are squamous cell carcinoma; in Western countries, in contrast, 50% of esophageal cancers are adenocarcinomas. We focus on the miRNA expression profiles of squamous cell type esophageal cancer to reveal the oncogenic mechanism through the posttranscriptional miRNA pathway. The purposes of this study were as follows: 1) miRNA expression profiling of squamous cell esophageal cancers to identify esophageal-cancer-specific miRNA signatures for a new class of diagnostic and prognostic biomarkers; and 2) clarifying the functional role(s) of miRNAs in esophageal cancer. Our preliminary studies suggest that some miRNAs (e.g., MIRN21) are promising biomarkers associated with esophageal cancer (Akagi et al. manuscript in preparation). Our miRNA study should provide new information on esophageal cancer. This study was supported in part by the Maruyama Memorial Research Fund of Nippon Medical School.

References

- 1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
- 2. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431: 343-349.
- van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103: 919–928.
- 4. Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key player in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27: 5959–5974.
- Tili E, Michaille JJ, Costinean S, Croce CM: MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 2008; 4: 534–541.

Journal Website (http://www.nms.ac.jp/jnms/)